drugset / Trial / NCT04858620

A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection

NCT04858620

Phase 3 Withdrawn Larkin Community Hospital
RandomizedCrossoverSingle-blindTreatment

Summary

This study aims to find out the efficacy of Xlear nasal spray as an adjunct medication against COVID-19. This encompasses reduction in the number of days to negativization via nasal swab PCR from the average 14 days and early improvement of symptoms.

Timeline

Start
2020-08-30
Primary completion
2021-08-30
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Grapefruit Seed Extract Unknown Intranasal
Subject Xylitol Small molecule Intranasal

Indications